SCHEMBL3209128

SCHEMBL3209128

Cc1ccc(NC(=O)Nc2sc3c(c2C(=O)N2CCN(C)C(=O)C2(C)C)CCOC3)cc1-c1ccc(CN2CCOCC2)nc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 8/20 0.38
CNR1 P21554 5/20 0.38
MAPK14 Q16539 2/20 0.35
ABL1 P00519 3/20 0.34
RAF1 P04049 3/20 0.34
LYN P07948 2/20 0.34
MAPK9 P45984 2/20 0.34
SRC P12931 1/20 0.34
BRAF P15056 2/20 0.34
EGFR P00533 1/20 0.34
EPHA2 P29317 1/20 0.34
EPHA3 P29320 1/20 0.34
AKT1 P31749 1/20 0.34
RORC P51449 1/20 0.34
KDR P35968 3/20 0.34
KIT P10721 2/20 0.34
TEK Q02763 1/20 0.34
PDE7A Q13946 1/20 0.34
ANO1 Q5XXA6 1/20 0.33
PDGFRB P09619 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13487806 0.84 RAF1 (0.37) MAPK14ABL1RAF1LYNMAPK9
SCHEMBL196602 0.84 MAPK14 (0.40) MAPK14ABL1RAF1LYNMAPK9
SCHEMBL195451 0.83 MAPK14 (0.39) MAPK14ABL1RAF1LYNMAPK9
SCHEMBL13487855 0.82 HIF1A (0.38) MAPK14ABL1RAF1LYNMAPK9
SCHEMBL3218816 0.82 MAPK14 (0.37) CNR2CNR1MAPK14ABL1RAF1
SCHEMBL195725 0.81 MAPK14 (0.42) MAPK14ABL1RAF1LYNMAPK9
SCHEMBL13487805 0.79 RAF1 (0.40) MAPK14ABL1RAF1LYNMAPK9
SCHEMBL3197206 0.79 RAF1 (0.42) CNR2MAPK14ABL1RAF1LYN
SCHEMBL3203963 0.78 MAPK14 (0.39) MAPK14
SCHEMBL3206459 0.77 RPS6KB1 (0.41) MAPK14ABL1EGFRKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010019930-A1 UREA DERIVATIVES AS INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 WO disclosed
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 US disclosed
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 US disclosed
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES MAP4K2, MAP3K1, MAP3K20 CNR2 4569/4885CNR1 4611/4885MAPK14 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.